Stéphane Boissel, CEO

Stéphane was appointed Chief Executive Officer of SparingVision concurrently to the first closing of the series A financing in August 2020.

He was previously Chairman of the Board of the Company. Prior to joining SparingVision as CEO, Stéphane served as Executive Vice President of Corporate Strategy of Sangamo Therapeutics, based in San Francisco (USA). He joined Sangamo Therapeutics in 2018 on the back of the acquisition by the latter of TxCell SA, a CAR-Treg company he was the CEO of. Stéphane is an experienced biotech professional who brings over 25 years of leadership experience across corporate finance, strategy and business development. Prior to his appointment as CEO of TxCell in 2015, he served as CEO of Genclis, a molecular diagnostics company. From 2002 to 2010, he served as CFO then Deputy-CEO of Innate Pharma SA, and from 2010 to 2014 he served as Deputy-CEO of Trangene SA. Earlier in his career, Stéphane worked in investment banking for Lazard, where he focused on principal investment in France, Singapore and Hong Kong. He also served as board member or Chairman of the board in different companies in the tech and biotech spaces across different countries.

Mr. Boissel completed his undergraduate work in management and finance at the University of Lyon and Paris-Dauphine in France and received his M.B.A. from the University of Chicago.

Stéphane is based on both sides of the ocean.

Dan Chung, CMO

Dr. Chung was appointed Chief Medical Officer of SparingVision in February 2021. In his role, he leads the clinical development and research into SPVN06, SparingVision’s flagship development asset, and is responsible for the clinical development of current and future pipeline products. Dr. Chung also leads the education of the medical community and patient advocacy.

Prior to joining SparingVision as CMO, Dr. Chung led the global medical strategy for ophthalmology at Spark Therapeutics, a leading rare disease gene therapy company and a member of the Roche Group. He played a pivotal role in the clinical development and approval of Luxturna™, the first gene therapy to be approved in the US for a genetic disease. During his time at Spark he served as the inherited retinal disease and ophthalmology expert across various company divisions and worked in medical affairs, clinical development and patient advocacy. Prior to Spark, Dr. Chung worked for 11 years at the Scheie Eye Institute within the Perelman School of Medicine at the University of Pennsylvania, specialising in gene-based therapies for inherited retinal diseases and cilia mediated disease.

Dr. Chung received his medical degree from the New York College of Osteopathic Medicine in 1994 and undertook postgraduate training at the National Eye Institute, Summa Health Systems and Cole Eye Institute at the Cleveland Clinic Foundation.

Dr. Chung is based in Philadelphia, USA.

Myriam Marussig, COO

Myriam was appointed Chief Operating Officer of SparingVision in October 2017 to undertake the operational translation of the SPVN06 gene therapy candidate from Institut de la Vision into Development.

Prior to joining SparingVision, Myriam served as Senior Director of preclinical and early clinical development of Genticel, based in Toulouse (FR). She joined Genticel, a spin-off of the Pasteur Institute, in 2004, to implement the development of an HPV therapeutic vaccine based on a new antigen delivery system. As Scientific Project leader and Director of Development, she led the translation of basic scientific findings into GMP manufacturing to clinical Phase 2. To support the Development strategy and plan, she built internal teams and strong long-term networks of CRO, experts, investigators and KOLs while participating at the fund raising and IPO. Myriam is an experienced biotech professional who brings over 20 years of leadership experience of team and project management across R&D, preclinical, manufacturing, clinical operations, regulatory affairs and strategy. Prior to her appointment at Genticel in 2004, she served as multi-project manager at Biovector Therapeutics, a gene and antigen delivery system company. Earlier in her career, Myriam worked 10 years in academic research at INSERM in Pitié-Salpêtrière Hospital (Paris) and then at the Karolinska Institute (Stockholm, SE).

Myriam obtained a PhD in Life Sciences from Paris XI University. Her postdoctoral work at the Karolinska Institute and the University of Stockholm focused on the identification of immunobiological mechanisms and treatments in different viral and parasitic diseases.

Myriam is based in Paris, France


Florence Lorget, CDSO

Florence was appointed Chief Development Sciences Officer of SparingVision.

From 2018 to 2020, Florence was the Senior Director for Nonclinical Safety Evaluation at Sangamo Therapeutics, a genomic medicine company, where she oversaw the pharmacology, toxicology and PK activities for a large portfolio of gene editing, gene regulation and gene therapy programs in various therapeutic areas. Prior to Sangamo, from 2013 to 2018, she was a Senior Scientist in the Safety Assessment department at Genentech. There, she was the Toxicology Therapeutic Area Lead for Ophthalmology. She also led the Ocular Platform Team, a cross-functional team focusing on the early development of long acting delivery strategies. From 2007 to 2013, Florence was a Senior Pharmacologist/Toxicologist at BioMarin where she was a key contributor to the nonclinical development of Vimizim®, an enzyme replacement therapy for Morquio syndrome, a rare lysosomal storage disorder, and of Vosoritide, a C-type natriuretic peptide for the treatment of Achondroplasia. Florence started her industry career at Amgen working on the Avimer™ technology. Florence obtained a Master in Bioengineering from the University of Technology of Compiegne (France). She received a Pharm D and a PhD in Cellular and Molecular Biology from the University of Picardie- Jules Verne (France).

Her postdoctoral work at the Nestle Research Center (Lausanne, Switzerland) and at the University of California San Francisco (UCSF) focused on osteoclast biology and the role of TGF-b on mesenchymal stem cell biology, respectively. Dr. Lorget has been a Diplomate of the American Board of Toxicology since 2014.

Florence is based in San Francisco, USA

Rajiv Gangurde, CTO

Dr. Rajiv Gangurde joined SparingVision as Chief Technology Officer in October 2020. In this role, he oversees technical operation activities including process and analytical development, manufacturing, and quality assurance.

Rajiv has over 14 years of industry experience in biopharmaceutical development, harnessed in the biotechnology hub of Massachusetts, USA. Most recently, Rajiv served as Senior Director and Head of Chemistry, Manufacturing and Controls (CMC) at Voyager Therapeutics, a gene therapy company based in Cambridge, MA. In this role, he was responsible for CMC strategy and management of the company’s entire gene therapy portfolio. Prior to Voyager, Rajiv was Director of Bioprocess Development and Manufacturing at Genocea Biosciences, where he led upstream and downstream process development and biochemistry groups for early- and late-stage recombinant-protein-based therapeutic vaccines. Prior to Genocea, Rajiv served as Head of Protein Sciences at LakePharma (previously called, Blue Sky Bioservices), leading therapeutic protein production efforts for pre-clinical studies.

Rajiv obtained his Ph.D. in Life Sciences from Mumbai University in India and did postdoctoral research at the Department of Biochemistry at the New Jersey Medical School, and at the Department of Molecular and Cellular Biology at Harvard University.

Rajiv is based in Massachusetts, USA.

Stanislas Piot, CFO

Stanislas Piot was appointed Chief Financial Officer of SparingVision in March 2020. He was previously CFO of Balyo an industrial robotic company based in Paris area where he prepared and managed the IPO on the Paris Stock market in 2017 and supported the growth of the company.

He started his career at Banque Worms in Hong Kong and then joined the capital market teams of Crédit Lyonnais in Paris before joining Oddo in 2000, where he specialized in M&A and IPOs of growth stocks. Then, he moved to Natixis, where he spent three years before joining Ipsogen in October 2007 as CFO managing the IPO on the Alternext market in June 2008.

Stanislas Piot then worked at Stentys from May 2010 until March 2017.He is a graduate of Université de Paris II in Econometrics and Finance. Stanislas is based in France

Stanislas is based in Paris, France